Thoratec Announces FDA Approval of HeartMate II(R) for Destinati... (y size could not be randomized to the la...)

Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy

Date:1/20/2010

y size could not be randomized to the larger HeartMate XVE. The filing also included data on adjunctive cohorts totaling an additional 409 patients, including those who had been originally supported by a HeartMate XVE, and based on the need for device replacement, elected to receive a HeartMate II, as well as patients enrolled under Continuous Access Protocols (CAPs).

"This is truly a momentous day for the hundreds of thousands of underserved advanced-stage heart failure patients," noted Gary F. Burbach, president and chief executive officer of Thoratec. "Those who now have access to the device owe a great deal to the patients and clinicians who participated in this landmark trial.

"As the data from both the trial and the BTT commercial experience with the device demonstrate, the HeartMate II is a proven therapy that extends patients' lives while providing them a significantly improved quality of life. We have been laying the groundwork for the DT launch through both our device manufacturing initiatives and market development programs targeted to clinicians and the 76 centers that have received certification from Centers for Medicare and Medicaid Services (CMS) for DT reimbursement. In addition, this approval will facilitate our initiatives to build upon our already strong presence in Europe," he added.

As a condition of approval, Thoratec has agreed to a post-approval study of 247 patients who will be followed until outcome or two years, whichever occurs first. Thoratec will utilize the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) to collect the FDA-required data on outcomes, adverse events, functional status and quality of life. Thoratec has also agreed to conduct a second small study at three specific centers to collect data regarding the relationship between bleeding, thrombosis, von Willebrand syndrome and anticoagulation in
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Presentation at Canaccord Adams Conference to be Webcast
5. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
6. Thoratec Presentation at Piper Jaffray Conference to be Webcast
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947

Post Your Comments:

(Date:6/18/2013)... 18, 2013 Decision Resources, one of the world,s ... finds that, over the past 12 months, 25 percent of ... Germany , Italy , ... Kingdom ) have been required to change the antiretroviral ... primarily to reduce costs. Additionally, more than 40 percent of ...

(Date:6/18/2013)... YORK , June 18, 2013 JDRF and ... are accelerating the development of new products that combine BD,s ... collaboration announced today. This new, three-year commitment is an extension ... Many patients with T1D not only take daily ... be placed in the body for a number of days ...

(Date:6/18/2013)... 18, 2013 Today, Wall Street Reports ... GILD ), Health Management Associates Inc. (NYSE: ... ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius ... free of charge - including full price targets, industry analysis ... Gilead Sciences, Inc. Research Report On June 7, ...

Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2 One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3 JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2 JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6

[0] One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs [0] JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes [0] Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics

... presented at,the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) ... continue,to offer new and better treatment options for breast ... for longer if the medicines are,given before and after ... , , Key data ...

... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced ... AZ-004 (Staccato(R) loxapine). This Phase 3,clinical trial was ... Both the 5 mg and 10 mg doses of ... a statistically significant reduction in,agitation from baseline to the ...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

(Date:6/18/2013)... York (PRWEB) June 19, 2013 Parker ... the rights of victims injured by dangerous drugs and ... an Arizona woman who alleges that she was ... filed on May 30th in the U.S. District Court ... No. 2:13-cv-12677) in the multidistrict litigation entitled In Re: ...

(Date:6/18/2013)... Colorado (PRWEB) June 18, 2013 Daily Gossip ... latest product reviews and useful articles. , The magazine ... introducing them to a new anabolic recipe every week ... Book is the perfect guide for readers who are ... , Reporters at Daily Gossip reveals that anabolic food is ...

(Date:6/18/2013)... 18, 2013 The Temp1000IS temperature ... stand-alone device which can be used to automatically record ... enclosure of the Temp1000IS comes with the serial number ... IFC400 (sold separately) docking station and can ... communications. No more removal of end-caps to download data. ...

(Date:6/18/2013)... Palo Alto has taken yet another step in ... its recent major long-term solar power commitment. , Last ... power purchase agreements , which together will result in the ... electric power per year, which is the equivalent of roughly ... power to supply all 65,000+ Palo Alto residents---and then some! ...

(Date:6/18/2013)... 18, 2013 Internationally acclaimed plastic ... website, thebestbreast.com, showcasing his unique approach to breast ... about his surgical method and highlights the results ... his website, Dr. Tebbetts compares his breast augmentation ... Dr. Tebbetts’ method does not necessitate the use ...

Breaking Medicine News(10 mins):Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3 Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4 Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2 Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2 Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2 Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3 Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2

[0] Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman [0] Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders [0] MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger [0] Palo Alto Seals the Deal on Major Solar Electric Investments [0] Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website

... visually impaired, navigating city streets or neighborhoods has constant challenges. ... rudimentary technologya simple caneto help them make their way through ... California engineering researchers is working to change that by developing ... design first shown a year ago is now being further ...

... Steven Reinberg HealthDay Reporter , WEDNESDAY, May ... prescribed drugs, the antidepressant Paxil and the cholesterol-lowering medication ... new study finds. The increase is most apparent ... is already too high, the researchers noted. "This ...

... 2011) The Maryland Stem Cell Research Commission (Commission) ... in response to its three FY 2011 Requests for ... Technology Development Corporation (TEDCO) approved the Commission,s recommendation to ... Research Fund,s (MSCRF) $10.4 million FY 2011 budget. ...

... May 25 (HealthDay News) -- The Internet has put the ... also allowed banned or controlled substances to slip within their ... online May 19 in Drug Testing and Analysis , ... contain ingredients other than those claimed and can be hazardous. ...

... obese women with less-than-optimal levels of vitamin D who lose ... increases in circulating levels of this fat-soluble nutrient, according to ... Center. , "Since vitamin D is generally lower in persons ... account, in part, for the link between obesity and diseases ...

... known for years that playing violent video games causes ... a new University of Missouri (MU) study provide one ... video game players become less responsive to violence, and ... "Many researchers have believed that becoming desensitized to ...

Cached Medicine News:Health News:'Guide vests' -- robotic navigation aids for the visually impaired 2 Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 2 Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 3 Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 2 Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 3 Health News:Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds 2 Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 2 Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 3 Health News:Violent video games reduce brain response to violence and increase aggressive behavior 2

'Guide vests' -- robotic navigation aids for the visually impaired Combo of Paxil, Pravachol May Raise Blood Sugar Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women Violent video games reduce brain response to violence and increase aggressive behavior

Inquire...

... Anatomical Malar I Implants - Providing ... implant follows the contour of the zygoma ... prominence. Anatomical Malar II Implants - ... the surgeon with another augumentation option that ...

... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...

Medicine Products:

Surgiform® Nasal Implants Taylor Posterior Mandibular Angle™ Implant Augmentation Malar Implants Extended Chin Implants